KANEKA
19.1.2023 04:57:38 CET | Business Wire | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has decided to increase its GMP*1 manufacturing capacity for mRNA*2 in Kaneka Eurogentec S.A. (Headquarters: Liège, Belgium; President: Lieven Janssens), a wholly owned group company in Europe. We plan to start operation sequentially from the end of 2023 with a capital investment of 2 billion JPY and a production capacity that is around 5 times higher than the current capacity. Kaneka Eurogentec S.A. will grow as a leading company of biopharmaceutical CDMO*3, responding to the vigorous global demand for mRNA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230118006042/en/
Kaneka Eurogentec S.A. building (Photo: Business Wire)
mRNA, which has been rapidly implemented in vaccines against COVID-19, is expected to be applied not only to vaccines for other infectious diseases but also to therapeutics for genetic diseases, cancer and so on. The demand for GMP manufacturing of mRNA will increase drastically with the active development of biopharmaceutical pipelines by pharmaceutical companies worldwide.
Kaneka Eurogentec S.A. is a CDMO for biopharmaceuticals inspected by the US FDA*4 and has world-class technology for producing plasmid DNA*5 and GMP manufacturing track records of over 25 years. They provide plasmid DNA, recombinant proteins, oligonucleotide*6 and so on as drug substances for pharmaceutical companies worldwide. In addition, Kaneka Eurogentec S.A. has started GMP manufacturing services for mRNA since 2020, and this capacity expansion will be utilized to expand the CDMO business.
Regarding the priority area of Health Care, Kaneka will continue to provide solutions globally for health issues through the growth of its biopharmaceutical business.
*1. |
GMP (Good Manufacturing Practice): A system for ensuring that products are consistently produced and controlled according to quality standards. |
*2. |
mRNA: An RNA molecule that is transcribed genetic information of protein synthesis from DNA. It is expected to be used as vaccines and therapeutics. |
*3. |
CDMO: Contract Development and Manufacturing Organization. |
*4. |
Food and Drug Administration (FDA): US governmental agency dealing with approval and supervision of violation of products which may be used by consumers in their daily life such as pharmaceutical products, cosmetics, medical devices, veterinary drugs and toys. |
*5. |
plasmid DNA: A general term for circular DNA molecules that exist outside the nucleus of bacteria such as E. coli and yeast, and that are passed down to daughter cells through cell division. |
|
It is conventionally used in processes for producing biopharmaceuticals such as therapeutic proteins and has been applied to genetic medicines and vaccines in recent years. |
*6. |
Oligonucleotide: Short polymeric sequences of nucleotides (RNA or DNA). It is used as drug substance of nucleic acid therapeutics. |
[General description of Kaneka Eurogentec S.A.]
Headquarters: Liège, Belgium
President: Lieven Janssens
Description of business: Manufacturing and sales of proteins, nucleic acids and peptides for medicinal, diagnostic and basic research uses
Established: 1985
Capital: 31 million euros
URL: http://www.eurogentec.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118006042/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom